Prof. Dr. Helga Rübsamen-Schaeff

Research Priorities: Infectious diseases, antiviral medications and antibiotics, development of therapeutic drugs, new active ingredients (e.g. against herpes, cytomegalovirus, HIV, hepatitis B, and multi-resistant bacteria), oncogenes
Helga Rübsamen-Schaeff is a chemist and a biochemist. She managed for 13 years the department of infectious disease research in a multinational large pharma company before successfully founding biopharmaceutical company and leading it as CEO. She is particularly interested in researching and developing antiviral medications (e.g. against herpes viruses, cytomegalovirus, HIV, and hepatitis B) as well as new antibiotics against multi-resistant pathogens. In her academic career she investigated genes by which viruses transform normal cells into cancer cells (oncogenes). Helga Rübsamen-Schaeff is an active supporter of a close cooperation between academic research and industry.
Initially, Helga Rübsamen-Schaeff was interested in oncology. She studied biochemical mechanisms of malignant transformation of oncogenic viruses and described several human genes which control cell growth.
Subsequently, Helga Rübsamen Schaeff was the first to isolate HIV strains from patients in Germany and, by doing so, described the virus’ variation ability. As part of a global collaboration effort with the World Health Organization (WHO), she worked on the systematic classification of HIV variants. She developed HIV tests and strategies for inhibiting the virus by drugs. On the basis of joint research, two pharmaceutical companies developed drug candidates against HIV.
In subsequent years, she researched therapeutic drugs against the viral hepatitis pathogens B and C, against herpes simplex virus and cytomegalovirus and multiresistant bacteria. In 2006, Helga Rübsamen-Schaeff founded the biopharmaceutical company AiCuris Anti-infective Cures. The company’s main areas of priority are new antiviral and antibacterial agents against life-threatening infectious diseases. A drug against cytomegalovirus reached the market in 2017.
Almost all active ingredients from Helga Rübsamen-Schaeff´s research have novel mechanisms of action and inhibit diseases with new chemical molecules. For example, an active ingredient against herpes simplex directly attacks an enzyme of the pathogen which the virus requires in order to multiply. In clinical trials, this drug shows an effect superior to existing medications. Rübsamen-Schaeff also described a new mechanism of action for the inhibition of the hepatitis B virus (the inhibition of the core antigen), which has since become the subject of intensive pharmaceutical research in many companies and academic institutions worldwide.
One of the medications stemming from her research has already been approved and introduced on the market (see above). For this innovation, Helga Rübsamen-Schaeff and her team were awarded the German Future Prize by the Federal President. The medication is an inhibitor of the cytomegalovirus. Human cytomegalovirus (HCMV) is widespread throughout the population and can become very dangerous in all situations in which the immune system is weakened. For people requiring organ transplants, it can cause severe and life-threatening illnesses. The medication allows patients to be treated prophylactically directly following a stem cell transplant, thus protecting them from the dangerous virus. The decisive clinical study was able to demonstrate a survival advantage for those receiving this treatment. A study testing the drug for kidney recipients was successful as well. International studies for treatment of other conditions of immune incompetency including the HIV-infection are under way.
The discovery of new antibiotics is a significant challenge. There is a growing number of infections due to multi-resistant bacteria for which the number of effective antibiotics is shrinking. Thus, an effort was also directed at the discovery of resistance breaking novel antibiotics – again looking for novel modes of action and novel chemical matter.